- Home
- LPTX vs NEUP Comparison
LPTX vs NEUP Comparison
Compare LPTX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- NEUP
- Stock Information
- Founded
- LPTX 2011
- NEUP 1996
- Country
- LPTX United States
- NEUP United States
- Employees
- LPTX N/A
- NEUP N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- NEUP
- Sector
- LPTX Health Care
- NEUP
- Exchange
- LPTX Nasdaq
- NEUP Nasdaq
- Market Cap
- LPTX 11.1M
- NEUP 12.7M
- IPO Year
- LPTX N/A
- NEUP N/A
- Fundamental
- Price
- LPTX $0.75
- NEUP $18.37
- Analyst Decision
- LPTX Hold
- NEUP Strong Buy
- Analyst Count
- LPTX 1
- NEUP 2
- Target Price
- LPTX N/A
- NEUP $28.00
- AVG Volume (30 Days)
- LPTX 7.6M
- NEUP 94.0K
- Earning Date
- LPTX 11-12-2025
- NEUP 11-15-2025
- Dividend Yield
- LPTX N/A
- NEUP N/A
- EPS Growth
- LPTX N/A
- NEUP N/A
- EPS
- LPTX N/A
- NEUP N/A
- Revenue
- LPTX N/A
- NEUP $15,649,448.00
- Revenue This Year
- LPTX N/A
- NEUP N/A
- Revenue Next Year
- LPTX N/A
- NEUP N/A
- P/E Ratio
- LPTX N/A
- NEUP N/A
- Revenue Growth
- LPTX N/A
- NEUP N/A
- 52 Week Low
- LPTX $0.22
- NEUP $2.90
- 52 Week High
- LPTX $4.79
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- LPTX 63.63
- NEUP 69.20
- Support Level
- LPTX $0.46
- NEUP $10.47
- Resistance Level
- LPTX $0.98
- NEUP $21.31
- Average True Range (ATR)
- LPTX 0.11
- NEUP 1.84
- MACD
- LPTX 0.03
- NEUP 0.71
- Stochastic Oscillator
- LPTX 51.58
- NEUP 72.11
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.